tetano
Editor, Senior Moderator
Rev Inst Med Trop Sao Paulo. 2018 Dec 20;61:e4. doi: 10.1590/S1678-9946201961004.
[h=1]Safety assessment of seasonal trivalent influenza vaccine produced by Instituto Butantan from 2013 to 2017.[/h] Gatt?s VL[SUP]1[/SUP], Braga PE[SUP]1[/SUP], Koike ME[SUP]1[/SUP], Lucchesi MBB[SUP]1[/SUP], Oliveira MMM[SUP]1[/SUP], Piorelli RO[SUP]1[/SUP], Queiroz V[SUP]1[/SUP], Precioso AR[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Vaccination has been a successful strategy in influenza prevention. However, despite the safety and efficacy of the vaccines, they can cause adverse events following immunization (AEFI). Moreover, due to the vaccination success, most of vaccine-preventable diseases (VPD) have become rare, and public attention has been shifted from VPD to the AEFI associated with vaccination. This manuscript describes the safety of Instituto Butantan (IB) seasonal trivalent influenza vaccine (TIV) from 2013 to 2017. AEFI data were received by the Department of Pharmacovigilance of IB (PV-IB), from January the 1st 2013 to December the 31st 2017, and were recorded in an electronic database (OpenClinica?). PV-IB received 1,415 Individual Case Safety Reports (ICSR) associated with the TIV; 1,253 ICSR with at least one AEFI were analyzed and 4,140 AEFI were identified. The other 162 (11.4%) cases did not present any symptom. Among the total of AEFI, 405 (9.8%) were classified as serious. AEFI with the highest incidence rates per 100,000 doses of TIV were: "local pain" (0.28), "local erythema" (0.23), "local warmth" (0.22), "local swelling" (0.20) and "fever" (0.19). PV-IB received 175 (4.2%) occurrences of SAE of special interest, of which 75 (1.8%) anaphylaxis/anaphylactic reactions, 56 (1.4%) neurological syndromes (including seven Guillain-Barr? Syndrome) and 44 (1.1%) convulsion/febrile convulsion. The results of this manuscript suggested that Instituto Butantan trivalent influenza vaccine (IB-TIV) is safe, as most of the reported AEFI were classified as non-serious. AEFI described for the IB-TIV are in agreement with the ones described in the literature for similar vaccines.
[h=4]TRIAL REGISTRATION:[/h] ClinicalTrials.gov NCT03057483.
PMID: 30570077 DOI: 10.1590/S1678-9946201961004
Free full text
[h=1]Safety assessment of seasonal trivalent influenza vaccine produced by Instituto Butantan from 2013 to 2017.[/h] Gatt?s VL[SUP]1[/SUP], Braga PE[SUP]1[/SUP], Koike ME[SUP]1[/SUP], Lucchesi MBB[SUP]1[/SUP], Oliveira MMM[SUP]1[/SUP], Piorelli RO[SUP]1[/SUP], Queiroz V[SUP]1[/SUP], Precioso AR[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Vaccination has been a successful strategy in influenza prevention. However, despite the safety and efficacy of the vaccines, they can cause adverse events following immunization (AEFI). Moreover, due to the vaccination success, most of vaccine-preventable diseases (VPD) have become rare, and public attention has been shifted from VPD to the AEFI associated with vaccination. This manuscript describes the safety of Instituto Butantan (IB) seasonal trivalent influenza vaccine (TIV) from 2013 to 2017. AEFI data were received by the Department of Pharmacovigilance of IB (PV-IB), from January the 1st 2013 to December the 31st 2017, and were recorded in an electronic database (OpenClinica?). PV-IB received 1,415 Individual Case Safety Reports (ICSR) associated with the TIV; 1,253 ICSR with at least one AEFI were analyzed and 4,140 AEFI were identified. The other 162 (11.4%) cases did not present any symptom. Among the total of AEFI, 405 (9.8%) were classified as serious. AEFI with the highest incidence rates per 100,000 doses of TIV were: "local pain" (0.28), "local erythema" (0.23), "local warmth" (0.22), "local swelling" (0.20) and "fever" (0.19). PV-IB received 175 (4.2%) occurrences of SAE of special interest, of which 75 (1.8%) anaphylaxis/anaphylactic reactions, 56 (1.4%) neurological syndromes (including seven Guillain-Barr? Syndrome) and 44 (1.1%) convulsion/febrile convulsion. The results of this manuscript suggested that Instituto Butantan trivalent influenza vaccine (IB-TIV) is safe, as most of the reported AEFI were classified as non-serious. AEFI described for the IB-TIV are in agreement with the ones described in the literature for similar vaccines.
[h=4]TRIAL REGISTRATION:[/h] ClinicalTrials.gov NCT03057483.
PMID: 30570077 DOI: 10.1590/S1678-9946201961004
Free full text